StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Research analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

Can-Fite BioPharma Trading Up 1.5 %

NYSE:CANF opened at $2.01 on Monday. The stock has a market capitalization of $7.12 million, a PE ratio of -1.10 and a beta of 1.53. The firm’s 50 day moving average is $2.16 and its 200 day moving average is $2.12. Can-Fite BioPharma has a 12 month low of $1.68 and a 12 month high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last issued its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Research analysts predict that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.